PV Bulletin

Regulatory intelligence & pharmacovigilance updates, mapped to your role.

Drug safety and regulatory intelligence for QPPV, Signal, Labeling, PV Ops, and Device Vigilance — daily briefings with operational next steps.

Need customization?Map custom PV workflows, roles, and reporting needs with us.

Topics we cover

Latest intelligence

publicEuropean Medicines Agency · European Union · Updated Jun 12, 2026

Introduction of Mandatory Annual Safety Report (ASR) Module in CTIS

Urgency: High

Clinical trial sponsors must update internal standard operating procedures (SOPs), conduct staff training on the functionality of the new ASR module, and utilize the CTIS training environment to ensure readiness for compliance with the new workflow.

ICSRCountry ComplianceRegulatory Intelligence Lead
SOP Impact2 SOPs
ConfidenceHigh
Relevant for: Regulatory Intelligence Lead, QPPV
verifiedRegulatory action: Notice
Read impact briefarrow_forward
publicEuropean Medicines Agency (EMA) · European Union · Updated Jun 12, 2026

Product Management Service (PMS) public API beta release - Technical registration requirements

Urgency: High

MAHs and technical teams must review the revised API registration requirements and implement necessary system updates to comply by the established timelines.

Country ComplianceICSRRegulatory Intelligence Lead
SOP Impact2 SOPs
ConfidenceHigh
Relevant for: Regulatory Intelligence Lead, QPPV
verifiedRegulatory action: Technical Guidance
Read impact briefarrow_forward
publicMedicines and Healthcare products Regulatory Agency (MHRA) · United Kingdom · Updated Jun 8, 2026

Field Safety Notice: Bolton Medical RelayPro Thoracic Stent-Graft System (NBS)

Urgency: High

Verify inventory of affected RelayPro Thoracic Stent-Graft System lots (model 28-N4-XX-XXX-XXS) and implement actions per the FSN document.

Signal ManagementLabelingRegulatory Intelligence Lead
SOP Impact2 SOPs
ConfidenceHigh
Relevant for: Regulatory Intelligence Lead, Signal Management Lead
verifiedRegulatory action: Field Safety Notice (FSN)
Read impact briefarrow_forward
publicMedicines and Healthcare products Regulatory Agency (MHRA) · United Kingdom · Updated Jun 8, 2026

Class 4 Defect Notification: Cadila Mirtazapine 30mg Tablets (EL(26)A/28)

Urgency: High

Check for affected batches of Mirtazapine 30mg Tablets as described in EL(26)A/28 and implement any necessary quarantining or recall steps.

Signal ManagementLabelingRegulatory Intelligence Lead
SOP Impact2 SOPs
ConfidenceHigh
Relevant for: Regulatory Intelligence Lead, Signal Management Lead
verifiedRegulatory action: Medicines Defect Notification (Class 4)
Read impact briefarrow_forward
publicFDA · USA · Updated Jun 5, 2026

GE HealthCare Infant Resuscitation System Air-Oxygen Blender Issue

Urgency: High

Identify and remove affected devices from use until corrected; if use is necessary, follow additional precautions provided in the GE HealthCare customer letter.

Signal ManagementLabelingRegulatory Intelligence Lead
SOP Impact2 SOPs
ConfidenceHigh
Relevant for: Regulatory Intelligence Lead, Signal Management Lead
verifiedRegulatory action: Early Alert
Read impact briefarrow_forward
publicSwissmedic · Switzerland · Updated Jun 5, 2026

Urgent Field Safety Notice (RECALL) - One-Piece Guedel Airways

Urgency: High

Identify and quarantine affected products. Return or destroy as instructed. Complete the reply form.

Signal ManagementLabelingRegulatory Intelligence Lead
SOP Impact2 SOPs
ConfidenceHigh
Relevant for: Regulatory Intelligence Lead, Signal Management Lead
verifiedRegulatory action: Field Safety Notice / Recall
Read impact briefarrow_forward
publicFDA · USA · Updated Jun 5, 2026

GE HealthCare Carestation Devices - Correction for Ineffective Ventilation in VCV Mode (FDA Class I Recall)

Urgency: High

Do not use VCV mode until corrected. Use PCV or PCV-VG mode. Perform Ventilation Screening Test. Return acknowledgement form to GE HealthCare.

Signal ManagementLabelingRegulatory Intelligence Lead
SOP Impact2 SOPs
ConfidenceHigh
Relevant for: Regulatory Intelligence Lead, Signal Management Lead
verifiedRegulatory action: Medical Device Recall / Correction
Read impact briefarrow_forward
publicEuropean Medicines Agency (EMA) · European Union · Updated Jun 5, 2026

EMA Updates Acceptable Intake Levels for Nitrosamine Impurities in Human Medicines

Urgency: High

Manufacturers must verify that their products meet the newly established acceptable intake levels for nitrosamines and implement necessary quality control measures to keep impurities within limits.

Signal ManagementLabelingRegulatory Intelligence Lead
SOP Impact2 SOPs
ConfidenceHigh
Relevant for: Regulatory Intelligence Lead, Signal Management Lead
verifiedRegulatory action: Regulatory Update
Read impact briefarrow_forward

Showing 17-24 of 101 updates